Comparison of clinical efficacy between twice-daily formoterol/budesonide combinations and once-daily fluticasone furoate/vilanterol in bronchial asthma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Jul 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Budesonide/formoterol (Primary) ; Vilanterol/fluticasone furoate (Primary)
Indications Asthma
Focus Therapeutic Use

13 Jul 2017 Status changed from recruiting to completed as per the results presented at the 113th International Conference of the American Thoracic Society
24 May 2017 Primary endpoint (Change from baseline (0 week) in FEV1 after 8 weeks of treatment, once-daily FF/VI versus twice-daily budesonide (BUD) / formoterol) has not been met as per the results presented at the 113th International Conference of the American Thoracic Society
24 May 2017 Results (n=21) presented at the 113th International Conference of the American Thoracic Society

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com